TY - JOUR
T1 - Peripheral mechanisms of peripheral neuropathic pain
AU - Pacifico, Paola
AU - Coy-Dibley, James S.
AU - Miller, Richard J.
AU - Menichella, Daniela M.
N1 - Publisher Copyright:
Copyright © 2023 Pacifico, Coy-Dibley, Miller and Menichella.
PY - 2023
Y1 - 2023
N2 - Peripheral neuropathic pain (PNP), neuropathic pain that arises from a damage or disease affecting the peripheral nervous system, is associated with an extremely large disease burden, and there is an increasing and urgent need for new therapies for treating this disorder. In this review we have highlighted therapeutic targets that may be translated into disease modifying therapies for PNP associated with peripheral neuropathy. We have also discussed how genetic studies and novel technologies, such as optogenetics, chemogenetics and single-cell RNA-sequencing, have been increasingly successful in revealing novel mechanisms underlying PNP. Additionally, consideration of the role of non-neuronal cells and communication between the skin and sensory afferents is presented to highlight the potential use of drug treatment that could be applied topically, bypassing drug side effects. We conclude by discussing the current difficulties to the development of effective new therapies and, most importantly, how we might improve the translation of targets for peripheral neuropathic pain identified from studies in animal models to the clinic.
AB - Peripheral neuropathic pain (PNP), neuropathic pain that arises from a damage or disease affecting the peripheral nervous system, is associated with an extremely large disease burden, and there is an increasing and urgent need for new therapies for treating this disorder. In this review we have highlighted therapeutic targets that may be translated into disease modifying therapies for PNP associated with peripheral neuropathy. We have also discussed how genetic studies and novel technologies, such as optogenetics, chemogenetics and single-cell RNA-sequencing, have been increasingly successful in revealing novel mechanisms underlying PNP. Additionally, consideration of the role of non-neuronal cells and communication between the skin and sensory afferents is presented to highlight the potential use of drug treatment that could be applied topically, bypassing drug side effects. We conclude by discussing the current difficulties to the development of effective new therapies and, most importantly, how we might improve the translation of targets for peripheral neuropathic pain identified from studies in animal models to the clinic.
KW - neuropathic pain
KW - nociception
KW - painful diabetic neuropathy
KW - peripheral neuropathic pain
KW - single cell RNA seq
UR - http://www.scopus.com/inward/record.url?scp=85172997302&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85172997302&partnerID=8YFLogxK
U2 - 10.3389/fnmol.2023.1252442
DO - 10.3389/fnmol.2023.1252442
M3 - Review article
C2 - 37781093
AN - SCOPUS:85172997302
SN - 1662-5099
VL - 16
JO - Frontiers in Molecular Neuroscience
JF - Frontiers in Molecular Neuroscience
M1 - 1252442
ER -